Comparative Pharmacology
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus MODAFINIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISDEXAMFETAMINE DIMESYLATE versus MODAFINIL.
LISDEXAMFETAMINE DIMESYLATE vs MODAFINIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisdexamfetamine is a prodrug of dextroamphetamine, which blocks the reuptake of norepinephrine and dopamine from the synaptic cleft and increases their release into the extraneuronal space.
The precise mechanism of action is unknown. Modafinil is a wakefulness-promoting agent that may have direct or indirect effects on dopamine, norepinephrine, serotonin, GABA, glutamate, and orexin systems. It binds to the dopamine transporter and inhibits dopamine reuptake.
30–70 mg orally once daily in the morning.
200 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life of lisdexamfetamine is approximately 1 hour (prodrug conversion), while dextroamphetamine (active moiety) has a half-life of 10-12 hours in adults. In children, half-life is slightly shorter (9-11 hours). Clinically, once-daily dosing provides symptom control for ADHD.
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateModafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Modafinil."
Clinical Note
moderateModafinil + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Modafinil."
Clinical Note
moderateModafinil + Erythromycin
Terminal elimination half-life is approximately 15 hours (range 10–30 hours). This supports once-daily dosing for sustained wakefulness.
Primarily renal: approximately 95% of the dose is excreted in urine, with about 70% as intact lisdexamfetamine, 20% as dextroamphetamine and its metabolites (hippuric acid, benzoic acid), and minimal biliary/fecal elimination (<5%).
Primarily renal (as metabolites and unchanged drug); approximately 80% of the dose is recovered in urine, with less than 10% as unchanged modafinil. Fecal excretion accounts for less than 1%.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Erythromycin can be decreased when combined with Modafinil."